https://old.dolon.com/2022/11/beyond-value-why-cell-and-gene-therapy-pricing-requires-new-thinking/ 2026-02-09T11:13:45+00:00 https://old.dolon.com/2023/03/paid-early-access-in-europe-is-it-needed-and-what-should-it-look-like/ 2026-02-09T11:14:39+00:00 https://old.dolon.com/2023/03/the-rituximab-effect-the-challenge-of-low-cost-and-off-label-comparators-in-rare-diseases/ 2026-02-09T11:14:42+00:00 https://old.dolon.com/2023/06/recommendations-for-better-use-of-quality-of-life-evidence-in-hta-for-rare-diseases/ 2026-02-09T11:14:55+00:00 https://old.dolon.com/2023/11/a-critique-of-the-critique-pharmaceuticals-value-price-and-profitability/ 2026-02-09T11:15:05+00:00 https://old.dolon.com/2024/03/exploring-alternative-pricing-approaches-for-orphan-medicines/ 2026-02-09T11:15:31+00:00 https://old.dolon.com/2024/10/pulling-back-the-curtain-on-joint-clinical-assessment/ 2026-02-09T11:15:51+00:00 https://old.dolon.com/2025/03/from-launch-to-legacy-pricing-excellence-through-forecasting-analytics/ 2026-02-09T11:16:36+00:00 https://old.dolon.com/2023/11/how-do-we-attain-sustainability-affordability-and-availability-of-car-t-therapies/ 2026-02-09T11:19:11+00:00 https://old.dolon.com/2022/01/burden-of-illness-assessment-evidence-generation/ 2026-02-19T16:50:53+00:00 https://old.dolon.com/2022/01/value-messaging-launch-support/ 2026-02-19T16:51:31+00:00 https://old.dolon.com/2022/01/ultra-orphan-drug-pricing-strategy/ 2026-02-19T16:51:40+00:00 https://old.dolon.com/2022/01/bespoke-analytics-financial-planning-tools/ 2026-02-19T16:51:55+00:00 https://old.dolon.com/2022/01/market-access-environment-policy-engagement/ 2026-02-19T16:52:03+00:00 https://old.dolon.com/2022/01/interactive-educative-pricing-exercise/ 2026-02-19T16:52:12+00:00 https://old.dolon.com/2011/09/estimating-the-budget-impact-of-orphan-medicines-in-europe-2010-2020/ 2026-02-19T17:30:01+00:00 https://old.dolon.com/2012/12/what-is-wrong-with-orphan-drug-policies-suggestions-for-ways-forward/ 2026-02-19T17:30:13+00:00 https://old.dolon.com/2013/12/a-pilot-study-of-multicriteria-decision-analysis-for-valuing-orphan-medicines/ 2026-02-19T17:30:24+00:00 https://old.dolon.com/2014/02/estimating-the-budget-impact-of-orphan-drugs-in-sweden-and-france-2013-2020/ 2026-02-19T17:30:38+00:00 https://old.dolon.com/2015/05/principles-for-consistent-value-assessment-and-sustainable-funding-of-orphan-drugs-in-europe/ 2026-02-19T17:30:49+00:00 https://old.dolon.com/2016/01/scientific-and-social-value-judgments-for-orphan-drugs-in-health-technology-assessment/ 2026-02-19T17:31:07+00:00 https://old.dolon.com/2017/03/recommendations-from-the-european-working-group-for-value-assessment-and-funding-processes-in-rare-diseases-orph-val/ 2026-02-19T17:31:15+00:00 https://old.dolon.com/2017/07/dealing-with-uncertainty-and-accounting-for-social-value-judgments-in-assessments-of-orphan-drugs-evidence-from-four-european-countries/ 2026-02-19T17:31:28+00:00 https://old.dolon.com/2018/12/projecting-pharmaceutical-expenditure-in-eu5-to-2021-adjusting-for-the-impact-of-discounts-and-rebates/ 2026-02-19T17:31:41+00:00 https://old.dolon.com/2019/02/hta-programme-response-to-the-challenges-of-dealing-with-orphan-medicinal-products-process-evaluation-in-selected-european-countries/ 2026-02-19T17:32:02+00:00 https://old.dolon.com/2019/12/an-analysis-of-orphan-medicine-expenditure-in-europe-is-it-sustainable/ 2026-02-19T17:32:15+00:00 https://old.dolon.com/2020/01/a-review-of-the-challenges-and-proposals-for-improving-patient-access-to-advanced-therapeutic-medicinal-products-in-europe/ 2026-02-19T17:33:11+00:00 https://old.dolon.com/2020/07/are-supplemental-appraisal-reimbursement-processes-needed-for-rare-disease-treatments-an-international-comparison-of-country-approaches/ 2026-02-19T17:33:22+00:00 https://old.dolon.com/2020/10/estimated-impact-of-eu-orphan-regulation-on-incentives-for-innovation/ 2026-02-19T17:33:40+00:00 https://old.dolon.com/2020/10/the-estimation-of-health-state-utility-values-in-rare-diseases-overview-of-existing-techniques/ 2026-02-19T17:33:53+00:00 https://old.dolon.com/2021/01/the-use-of-patient%e2%80%90reported-outcome-measures-in-rare-diseases-and-implications-for-health-technology-assessment/ 2026-02-19T17:34:06+00:00 https://old.dolon.com/2021/02/how-did-we-get-here-and-where-do-we-go-now-an-economists-perspective-on-eu-orphan-drug-policy/ 2026-02-19T17:34:18+00:00 https://old.dolon.com/2021/05/hta-appraisal-framework-suitable-for-rare-disease-treatments/ 2026-02-19T17:34:30+00:00 https://old.dolon.com/2021/05/examining-the-impact-of-different-country-processes-for-appraising-rare-disease-treatments-a-case-study-analysis/ 2026-02-19T17:34:37+00:00 https://old.dolon.com/2021/07/addressing-unmet-needs-in-extremely-rare-and-paediatric-onset-diseases-how-the-biopharmaceutical-innovation-model-can-help-identify-current-issues-and-find-potential-solutions/ 2026-02-19T17:34:53+00:00 https://old.dolon.com/2021/09/implementing-outcomes%e2%80%90based-managed-entry-agreements-for-rare-disease-treatments-nusinersen-and-tisagenlecleucel/ 2026-02-19T17:35:05+00:00 https://old.dolon.com/2021/09/consideration-of-quality-of-life-in-the-health-technology-assessments-of-rare-disease-treatments/ 2026-02-19T17:35:20+00:00 https://old.dolon.com/2022/01/exploring-the-economics-of-gene-therapy-innovation-and-price/ 2026-02-19T17:35:31+00:00 https://old.dolon.com/2022/02/double-bad-luck-should-rare-diseases-get-special-treatment/ 2026-02-19T17:35:38+00:00 https://old.dolon.com/2022/03/facilitating-more-efficient-negotiations-for-innovative-therapies-a-value-based-negotiation-framework/ 2026-02-19T17:35:47+00:00 https://old.dolon.com/2023/01/absence-of-comparative-survival-data-in-health-technology-assessment-of-oncology-therapies/ 2026-02-19T17:36:04+00:00 https://old.dolon.com/2023/02/introducing-the-dolon-institute/ 2026-02-19T17:36:11+00:00 https://old.dolon.com/2023/02/rare-disease-day-2023-why-do-rare-diseases-warrant-special-treatment/ 2026-02-19T17:36:17+00:00 https://old.dolon.com/2023/03/mapping-the-burden-of-severe-forms-of-epidermolysis-bullosa-implications-for-patient-management/ 2026-02-19T17:36:29+00:00 https://old.dolon.com/2023/08/innovative-contracting-for-atmps-in-europe-recent-learnings-from-the-manufacturer-experience/ 2026-02-19T17:36:35+00:00 https://old.dolon.com/2023/09/revision-of-the-orphan-regulation-estimated-impact-on-incentives-for-innovation-of-changes-proposed-by-the-european-commission/ 2026-02-19T17:38:06+00:00 https://old.dolon.com/2023/10/rare-innovation-how-it-happens-when-it-doesnt-and-what-can-be-done-to-sustain-it/ 2026-02-19T17:38:14+00:00 https://old.dolon.com/2023/11/revision-of-the-general-pharmaceutical-legislation-impact-assessment-of-european-commission-and-efpia-proposals/ 2026-02-19T17:38:40+00:00 https://old.dolon.com/2024/02/rare-disease-day-2024-what-does-it-take-to-see-continued-rare-disease-innovation-in-europe/ 2026-02-19T17:40:12+00:00 https://old.dolon.com/2024/05/revision-of-the-general-pharmaceutical-legislation-impact-assessment-of-key-orphan-proposals-on-member-states/ 2026-02-19T17:40:29+00:00 https://old.dolon.com/2024/05/evolution-of-willingness-to-pay-in-cost-effectiveness-countries-united-kingdom-australia-canada-and-sweden/ 2026-02-19T17:41:03+00:00 https://old.dolon.com/2024/10/gene-therapy-mini-series-introduction/ 2026-02-19T17:41:14+00:00 https://old.dolon.com/2024/10/gene-therapy-mini-series-promoting-multi-stakeholder-education-to-support-access-to-gene-therapy/ 2026-02-19T17:41:24+00:00 https://old.dolon.com/2024/10/gene-therapy-mini-series-enhancing-the-delivery-of-gene-therapy-through-specific-care-models-examining-centers-of-excellence/ 2026-02-19T17:41:31+00:00 https://old.dolon.com/2024/10/gene-therapy-mini-series-facilitating-effective-health-technology-assessment-for-gene-therapy/ 2026-02-19T17:41:38+00:00 https://old.dolon.com/2024/10/gene-therapy-mini-series-novel-payment-models-to-facilitate-patient-access-to-gene-therapy/ 2026-02-19T17:41:49+00:00 https://old.dolon.com/2025/01/2025-themes-for-pricing-and-access-success-for-rare-disease-and-oncology-medicines/ 2026-02-19T17:42:07+00:00 https://old.dolon.com/2025/03/what-do-the-new-medicare-negotiations-mean-for-pipeline-orphan-therapies/ 2026-02-19T17:42:54+00:00 https://old.dolon.com/2025/05/rare-disease-policy-in-high-income-countries-an-overview-of-achievements-challenges-and-solutions/ 2026-02-19T17:43:10+00:00 https://old.dolon.com/2025/09/the-transformative-value-of-cancer-medicines-in-europe/ 2026-02-19T17:43:20+00:00 https://old.dolon.com/2025/09/supporting-patients-with-underserved-autoimmune-diseases-challenges-and-opportunities-for-innovative-medicines/ 2026-02-19T17:43:30+00:00 https://old.dolon.com/2025/10/innovative-industry-perspective-assessing-the-proposed-regulatory-changes-and-their-impact-on-innovation-and-competitiveness-of-the-eu-regulatory-framework-as-part-of-the-eu-general-pharmaceutical-le/ 2026-02-19T17:43:37+00:00 https://old.dolon.com/2025/12/access-to-multi-indication-medicines-in-underserved-autoimmune-diseases-are-there-better-approaches-to-supporting-sustainable-access/ 2026-02-19T17:43:44+00:00 https://old.dolon.com/2026/02/why-orphan-medicines-remain-out-of-reach-in-low-and-middle-income-countries-and-what-can-be-done/ 2026-02-27T10:47:51+00:00 https://old.dolon.com/2025/02/rare-disease-day-2025-how-might-jca-impact-orphan-sustainability-in-europe/ 2026-02-27T10:48:44+00:00 https://old.dolon.com/2025/01/joint-clinical-assessment-the-finger-on-the-scale-for-orphan-sustainability-in-europe/ 2026-02-27T10:48:57+00:00 https://old.dolon.com/2023/09/als-a-rare-neurodegenerative-disease-european-landscape-assessment-and-policy-recommendations-for-improved-diagnosis-care-and-treatment/ 2026-03-04T21:50:28+00:00 https://old.dolon.com/2024/11/pricing-and-reimbursement-of-multiple-indication-medicines/ 2026-03-04T22:05:03+00:00 https://old.dolon.com/2026/03/press-release-prescient-acquires-dolon/ 2026-03-30T12:58:45+00:00 https://old.dolon.com/2026/05/future-proofing-hta-the-case-for-flexibility-in-assessment-frameworks/ 2026-06-09T09:15:55+00:00 https://old.dolon.com/2026/06/onward-driving-equitable-access-and-system-readiness-in-cancer-care-oncology-needs-workforce-access-research-disparities/ 2026-06-29T14:48:01+00:00 https://old.dolon.com/2026/07/dolon-is-moving-to-the-prescient-website/ 2026-07-13T14:55:32+00:00 https://old.dolon.com/2026/07/taiwan-perspectives-from-the-onward-iniative-advancing-equitable-access-and-system-readiness-in-cancer-care/ 2026-07-15T15:09:42+00:00